ORTH ANDREW C. 4
4 · Krystal Biotech, Inc. · Filed Jun 9, 2023
Insider Transaction Report
Form 4
ORTH ANDREW C.
Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-06-09$129.70/sh−333$43,189→ 100 total - Sale
Common Stock
2023-06-09$128.94/sh−6,906$890,488→ 433 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-06-09−12,500→ 37,500 totalExercise: $63.55Exp: 2032-02-27→ Common Stock (12,500 underlying) - Exercise/Conversion
Common Stock
2023-06-09$63.55/sh+12,500$794,375→ 12,600 total - Sale
Common Stock
2023-06-09$128.10/sh−5,261$673,958→ 7,339 total
Footnotes (5)
- [F1]The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share.
- [F2]The transaction was executed in multiple trades ranging from $127.5500 to $128.5400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F3]The transaction was executed in multiple trades ranging from $128.5600 to $129.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]The transaction was executed in multiple trades ranging from $129.5600 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F5]50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023.